By Kuldip K. Ambastha
BioNTech SE (BNTX) is aiming to become a leading biotechnology company with a main focus on individualized cancer medicine. The company has also been successful in offering an mRNA-based, two-shot coronavirus vaccine called BNT162b2 (aka: Comirnaty and Tozinameran), which has become increasingly important due to the rise of the highly contagious Delta (B.1.617.2) variant of COVID-19. On Monday, August 9, 2021, the stock of BioNTech SE had a +15.0% gain. A strong earnings announcement plus significant forecasted demand going forward helped with the stock’s price.
On Wednesday, August 11, 2021, the stock of BioNTech SE had a -13.8% loss. During the trading week, investor reluctance with high valuations led to a broad sell-off mainly in the technology and healthcare sectors, alongside a lesser sell-off in the biotechnology sector. This sell-off hurt the stock’s price. Due to concerns around the Delta variant, more and more new people of various age levels may get coronavirus vaccine shots and supplemental vaccine shot(s) may be needed for an already vaccinated individual. Depending on company-specific and industry-wide biotechnology news in the future, the stock price of BioNTech SE may keep fluctuating akin to what was seen in this past trading week.
Keywords – BioNTech SE, BioNTech, BNTX, biotechnology, biotech, technology, tech, healthcare, health care, COVID-19, coronavirus, pandemic, Delta, B.1.617.2, vaccine, mRNA, BNT162b2, Comirnaty, Tozinameran.
Disclosure – The principals and clients of Ambastha Financial LLC have no positions in BNTX.
Disclaimer – No recommendations are being made via this post. Past performance is not an indicator of future performance. As an investor, you should do your own research and seek professional advice from a Registered Investment Adviser (RIA). You can lose money by investing in stocks and other instruments. Ambastha Financial LLC does not assume any responsibility (legal or otherwise) for any losses that may occur as a result of actions taken based on this post. All content copyrighted © 2021 – Ambastha Financial LLC.